Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indomethacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 10/20 | 0.74 |
| ▸ | PTGS1 known ✓ | P23219 | 4/20 | 0.74 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.74 |
| ▸ | AKR1C2 | P52895 | 5/20 | 0.74 |
| ▸ | PPARG | P37231 | 3/20 | 0.74 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.74 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.74 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | PTGES | O14684 | 1/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | ALB | P02768 | 1/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indomethacin SCHEMBL6827247 | 0.93 | PTGS2 (0.63) | PTGS2AKR1C3AKR1C2PTGS1PPARG | |
| Indomethacin SCHEMBL8702320 | 0.92 | PTGS2 (0.80) | PTGS2AKR1C3AKR1C2PTGS1PPARG | |
| Indomethacin SCHEMBL11570993 | 0.90 | PTGS2 (0.79) | PTGS2AKR1C3AKR1C2PTGS1PPARG | |
| Indomethacin SCHEMBL356273 | 0.90 | PTGS2 (0.79) | PTGS2AKR1C3AKR1C2PTGS1PPARG | |
| Indomethacin SCHEMBL10863701 | 0.88 | PTGS2 (0.57) | PTGS2AKR1C3AKR1C2PTGS1PPARG | |
| Indomethacin SCHEMBL25313463 | 0.86 | PTGS2 (0.92) | PTGS2AKR1C3AKR1C2PTGS1PPARG | |
| Indomethacin SCHEMBL3518614 | 0.86 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1PPARG | |
| Indomethacin SCHEMBL29353712 | 0.86 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1PPARG | |
| Indomethacin SCHEMBL9300 | 0.86 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1PPARG | |
| Indomethacin SCHEMBL29525957 | 0.86 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111359007-B | Modified bacterial cellulose hydrogel dressing and preparation method thereof | 瑞希(重庆)生物科技有限公司 | 2022-01-11 | — | — | CN | claimed |
| CN-111359007-A | Modified bacterial cellulose hydrogel dressing and preparation method thereof | 瑞希(重庆)生物科技有限公司 | 2020-07-03 | — | — | CN | claimed |
| EP-1829528-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1829527-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-09-05 | — | — | EP | claimed |
| EP-1815846-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1815847-A2 | Aggregate with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin | IDEA AG (DE) | 2007-08-08 | — | — | EP | claimed |
| EP-1551370-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2005-07-13 | — | — | EP | claimed |
| WO-2004032900-A1 | AGGREGATE WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN | IDEA AG (DE) | 2004-04-22 | — | — | WO | claimed |
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | IDEA AG (DE) | 2004-04-15 | — | — | US | claimed |
| EP-1272218-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | claimed |
| EP-1146879-A4 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF RESTENOSIS WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | UNIV ROCKEFELLER (US) | 2002-07-03 | — | — | EP | claimed |
| EP-1146879-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF RESTENOSIS WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | THE ROCKEFELLER UNIVERSITY (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2001076576-A2 | A PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ACUTE, CHRONIC PAIN AND/OR NEUROPATHIC PAIN AND MIGRAINES | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | claimed |
| WO-2000033790-A2 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF ARTERIAL LESIONS WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | THE ROCKEFELLER UNIVERSITY (US) | 2000-06-15 | — | — | WO | claimed |
| WO-2000033848-A1 | METHODS AND COMPOSITIONS FOR PREVENTION AND TREATMENT OF RESTENOSIS WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | THE ROCKEFELLER UNIVERSITY (US) | 2000-06-15 | — | — | WO | claimed |
| US-20230357200-A1 | SMALL MOLECULE STIMULATORS OF STEROID RECEPTOR COACTIVATOR-3 AND METHODS OF THEIR USE AS CARDIOPROTECTIVE AND/OR VASCULAR REGENERATIVE AGENTS | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-09 | — | — | US | disclosed |
| US-11708350-B2 | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents | BAYLOR COLLEGE OF MEDICINE (US) | 2023-07-25 | — | — | US | disclosed |
| US-4976949-A | ACTIVE MATERIALS IN MICROSPHERES WITH CONTROLLED DENSITY AND DIAMETER FOR DELIVERY INTO INTESTINAL TRACT WITH MEALS | THE UNIVERSITY OF MICHIGAN (US) | 1990-12-11 | — | — | US | disclosed |
| US-4879274-A | IMPROVED ABSORPTION | KAO CORPORATION (JP) | 1989-11-07 | — | — | US | disclosed |
| EP-0216303-A2 | External medication | Kao Corporation (JP) | 1987-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | SLC43A1, TRPV2, TRPA1 | PTGS2 34/4885PTGS1 32/4885AKR1C3 1530/4885 |
| US-11708350-B2 | Small molecule stimulators of steroid receptor coactivator-3 and methods of their use as cardioprotective and/or vascular regenerative agents | NCOA3, FABP3, NCOA1 | PTGS2 351/4885PTGS1 173/4885AKR1C3 3412/4885 |
| US-20230357200-A1 | SMALL MOLECULE STIMULATORS OF STEROID RECEPTOR COACTIVATOR-3 AND METHODS OF THEIR USE AS CARDIOPROTECTIVE AND/OR VASCULAR REGENERATIVE AGENTS | NCOA3, FABP3, NCOA1 | PTGS2 351/4885PTGS1 173/4885AKR1C3 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.